COVID-19 poses to an individual.
Many people have questions about how the COVID-19 pandemic may affect them. “What will happen if I get infected?” “Will I have a severe immune response?” “Am I at risk for being hospitalized?”
EpiSwitch CST is the first and only commercially-available blood test to predict COVID-19 severity in ANY adult, independent of COVID-19 status. EpiSwitch CST is variant-agnostic, meaning that the test identifies risk due to regular SARS-CoV-2, as well against the delta and omicron strains.
The test is designed to provide you and your healthcare provider (HCP) with actionable decision-making information to reduce your risk of negative COVID-19 related health outcomes based on your unique 3D genetic immune profile.
How EpiSwitch CST can help
GAIN GREATER PEACE OF MIND
IDENTIFY YOUR RISK OF DEVELOPING A SEVERE IMMUNE RESPONSE
INFORM PREVENTIVE LIFESTYLE DECISIONS
EMPOWER VACCINATION DECISIONS
INSTILL THE CONFIDENCE TO SAFELY RETURN TO WORK
INFORM YOUR HCP’s ASSESSMENT
Features of EpiSwitch CST
EpiSwitch CST is the first and only prognostic blood test that can predict a severe immune response to future COVID-19 infection.
Helps identify individuals who would most likely require critical care.
Can be used by any adult, independent of their COVID-19 status––including those who have never been infected, those who have been infected, or those who are currently infected.
Conventional COVID-19 tests can only detect infection with SARS-CoV-2. They cannot predict whether an individual will have a severe immune response to COVID-19.
Knowledge of the EpiSwitch CST score allows HCPs and patients to formulate an effective management plan.
A molecular test from a routine blood draw with results in 48-72 hours.
The EpiSwitch CST report provides an
easy-to-understand assessment of risk for a severe immune response to COVID-19.
Sample results of EpiSwitch CST
Patient risk is presented as a single, easy-to-read EpiSwitch CST risk category, assessing the prognosis of patients if they become infected with SARS-CoV-2.
EpiSwitch CST includes clear guidance for interpretation of the risk category by a healthcare professional. Decisions on care and treatment should be based on the independent medical judgment of the treating HCP taking into consideration all available information.